Prof. Dr. Razvigor Darlenski

Assoc. Prof. Dr. Razvigor Darlenski
Acibadem Cityclinic Tokuda Hospital Sofia Bulgaria

What’s new in 2021 on atopic dermatitis treatment?
Autor: Assoc. Prof. Dr. Razvigor Darlenski

Atopic dermatitis (AD) is a paradigmatic chronic inflammatory skin disease characterized by a complex pathophysiology and a wide spectrum of the clinical phenotype. Despite this high degree of heterogeneity, AD is still considered a single disease and usually treated according to the “one-size-fits-all” approach.
In the past decade a great number of topical and systemic therapies have been introduced or are in the pipeline for AD pharmacological treatment. In this talk we summarize the current evidence-based knowledge on novel therapies for AD management.
Summarizing the evidence on well-known modalities such as calcineurin inhibitors, new agents such as crisaborole – a phosphodiesterase 4 inhibitor indicated for the treatment of mild to moderate AD. In addition to the biologic agent approved for moderate and severe AD, dupilumab, other biologic therapies and small molecules, i.e. Janus kinase inhibitors represent the progress in AD treatment in the middle of 2021. We highlighten the need for personalized approach in the management of this chronic inflammatory multisystem disease.

Scurt CV

Razvigor Darlenski is a dermatologist coming from Bulgaria. In 2014 he was selected as an associate professor at Trakia University, Stara Zagora. In 2010 he has defended a PhD thesis on the role of epidermal barrier for skin irritation and sensitization. Currently he is working as dermatologist at Tokuda Hospital Sofia, Bulgaria. Dr. Darlenski has published more than 70 papers in peer-reviewed journal and he is also an author of 12 book chapters. Dr. Darlenski is a member of the following organizations: Bulgarian Dermatological Society (BDS), member of the Honours & Awards committee of the European Academy of Dermatology and Venereology, Junior working group of the World Allergy Organization, European Academy of Allergology and Clinical Immunology, European Epidermal Barrier Research Network, European Network for Cutaneous Adverse Effects of Drugs (ENCAD), European Surveillance System on Contact Allergies, Union of Scientist in Bulgaria, Bulgarian Allergology Society, Bulgarian Medical Association, National Bulgarian Society of Aesthetic Surgery and Aesthetic Medicine, International society of skin physiology and pharmacology (ISP).
He is a winner of several awards among which Inaugural Edward L. Keyes award of the IACD for this meeting in Cancun (2012), Winner of the EER fellow award of the ESDR and ASDV (2013), Michael Hornsetin Memorial Scholarship of the EADV (2009).
His research interests are focused on skin barrier, drug reactions of the skin, skin irritation, contact allergy, urticaria, atopic eczema, and non-invasive methods in dermatology.